207results about How to "Prevent fibrosis" patented technology

Intraocular devices for use in and attached to the natural lens capsule of an eye are provided. The lens capsule may be maintained in a configuration to avoid post-operative changes that are deleterious to vision. Single or dual optic systems are provided, which may be accommodating. Combinations of devices to obtain dual optic systems are disclosed.

Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and / or holding the cardiac rhythm management device or other implantable medical device for the purpose of securing it in position, inhibiting or reducing bacterial growth, providing pain relief and / or inhibiting scarring or fibrosis on or around the CRM or other implantable medical device. Preferred embodiments include surgical mesh pouches coated with one or more biodegradable polymers that can act as a stiffening agent by coating the filaments or fibers of the mesh to temporarily immobilize the contact points of those filaments or fibers and / or by increasing the stiffness of the mesh by at least 1.1 times its original stiffness. The pouches of the invention can also provide relief from various post-operative complications associated with their implantation, insertion or surgical use, and, optionally, include one or more drugs in the polymer matrix of the coating to provide prophylactic effects and / or alleviate side effects or complications associated with the surgery or implantation of the CRM or other implantable medical device.

Biodegradable polymer-coated surgical meshes formed into pouches are described for use with cardiac rhythm management devices (CRMs) and other implantable medical devices. Such meshes are formed into a receptacle, e.g., a pouch or other covering, capable of encasing, surrounding and / or holding the cardiac rhythm management device or other implantable medical device and preventing or retarding the formation of a biofilm.

The invention discloses a nerve conduit and a preparation method thereof. The nerve conduit consists of an inner layer, an outer layer and at least one minitype cavity for storing a bioactive factor solution, wherein the inner layer is of a hydrophilic cell scaffold layer, and the outer layer is of a hydrophobic nerve conduit scaffold layer. The nerve conduit can further comprise a transition layer between the inner layer and the outer layer. The preparation method of the nerve conduit comprises the steps of preparing the inner layer by adopting an electrostatic spinning method, then adding the material for preparing the cavity, then preparing the outer layer, and taking out or dissolving the material for preparing the cavity, thus obtaining the nerve conduit. The nerve conduit has the minitype cavity, so that bioactive factors can be loaded by a manner of injection, soaking and the like as required before operation, thus not only leading the production quality to be easily controlled, but also being capable of greatly improving the survival rate of the bioactive factors, more efficiently promoting the regeneration of nerves, and enhancing the restoration effect of nerves.

The invention discloses an organ engineering tendon graft which comprises (a) biodegradable materials which can be accepted in pharmacy; (b) seed cells which can be inoculated to the biodegradable materials, and the seed cells are selected from the following groups: (i) fibroblasts, (ii) adipose-derived cells, or (iii) the mixture of the dermal fibroblasts and the adipose-derived cells with the ratio of 1:10000 to 10000:1. The graft is gotten from the cultivation of a complex of the seed cells and the biodegradable materials in a bioreactor, and the complex is obtained through the mixing of the seed cells and the biodegradable materials which can be accepted in pharmacy. The graft can be used for restoring the tendon defect.

A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.

The invention discloses application of miR-21 in preparation of medicine for treating intrauterine adhesion and / or thin inner membranes. The study finds that the miR-21 expression for endometrial epithelium cells and mesenchymal cells is obviously reduced, and particularly the decrease for epithelial cells is most remarkable. Moreover, in vitro results indicate that the EMT of the endometrial epithelium cells is inverted through miR-21, and fibrosis is inhibited. Therefore, the miR-21 possibly plays important roles in diagnose and treatment aspects of intrauterine adhesion and / or thin inner membranes, and can be used for preparing medicine for diagnosing and treating intrauterine adhesion and / or thin inner membranes or preparing medicine for treating other diseases related to womb fibrosis.

The invention relates to a method for constructing a cell transplantation slice by using human umbilical cord mesenchymal stem cells (hUC-MSCs) and anthropogenic amniotic membrane. The method comprises the following steps: taking the freshly collected anthropogenic amniotic membrane and umbilical cord, separating chorion from the amniotic membrane, treating the separated amniotic membrane by normal saline, and then cryopreserving for later use; cutting the umbilical cord into small pieces, and tearing Wharton's jelly off; cutting the Wharton's jelly into pieces, putting the cut Wharton's jelly onto a sterile culture vessel, adding a culture solution into the sterile culture vessel, and putting the sterile culture vessel into an incubator for culturing to obtain primary generation hUC-MSCs; adding pancreatin into a culture medium of the primary generation hUC-MSCs, digesting, and continuously culturing in the incubator to obtain the hUC-MSCs; carrying out sterile hydration on the cryopreserved standby amniotic membrane, then flatly laying the amniotic membrane on an amniotic membrane carrier thimble, and then moving into the sterile culture vessel; inoculating the hUC-MSCs in the culture vessel, and then culturing in the incubator to obtain the cell transplantation slice with cell confluence reaching up to 80-90%. The cell transplantation slice prepared by the method is capable of carrying out damage repair at specific parts, so that the defects of using the hUC-MSCs or amniotic membrane alone for treatment are overcome; therefore, a new treatment strategy is provided for refractory diseases, and a new therapy approach is opened up for the clinical application of stem cells.

A compound of formula (I) wherein variables are as defined herein having an autotaxin inhibitory effect and a pharmaceutical composition comprising the same.